270 related articles for article (PubMed ID: 21528770)
1. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
[TBL] [Abstract][Full Text] [Related]
2. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
3. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
4. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
[TBL] [Abstract][Full Text] [Related]
6. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
[TBL] [Abstract][Full Text] [Related]
7. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
Wraith JE
Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
[TBL] [Abstract][Full Text] [Related]
9. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
[TBL] [Abstract][Full Text] [Related]
10. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.
Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ
Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123
[TBL] [Abstract][Full Text] [Related]
11. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
Christianto A; Watanabe H; Nakajima T; Inazu T
Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
[TBL] [Abstract][Full Text] [Related]
13. Mucopolysaccharidosis type II, Hunter's syndrome.
Tylki-Szymańska A
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092
[TBL] [Abstract][Full Text] [Related]
14. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
Kim S; Whitley CB; Jarnes Utz JR
Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
[TBL] [Abstract][Full Text] [Related]
15. Idursulfase in Hunter syndrome treatment.
Zareba G
Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
[TBL] [Abstract][Full Text] [Related]
16. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
[TBL] [Abstract][Full Text] [Related]
18. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
19. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
Burton BK; Whiteman DA;
Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
